PSNL · Personalis, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.47M | - | $14.49M | $17.20M | $20.61M | - | $25.71M | $22.58M | $19.52M | - |
| Cost of Revenue | $15.19M | - | $12.58M | $12.45M | $13.40M | - | $16.96M | $14.54M | $14.03M | - |
| Gross Profit | $281.0K | - | $1.91M | $4.76M | $7.21M | - | $8.74M | $8.04M | $5.49M | - |
| R&D | $14.54M | - | $12.17M | $12.38M | $12.64M | - | $11.68M | $12.96M | $12.77M | - |
| SG&A | $17.90M | - | $13.03M | $14.18M | $12.26M | - | $11.44M | $11.97M | $11.60M | - |
| Total Operating Expenses | $47.63M | - | $37.79M | $39.01M | $38.30M | - | $40.09M | $39.47M | $38.41M | - |
| D&A | $2.37M | - | $2.76M | $2.50M | $2.59M | - | $2.80M | $2.80M | $2.84M | - |
| Operating Income | ($32.16M) | - | ($23.29M) | ($21.80M) | ($17.70M) | - | ($14.38M) | ($16.89M) | ($18.88M) | - |
| Interest Expense | $47.0K | - | $64.0K | $48.0K | $28.0K | - | $7.0K | $9.0K | $9.0K | - |
| Income Tax | $16.0K | - | $3.0K | $2.0K | $7.0K | - | $3.0K | $4.0K | $7.0K | - |
| Net Income | ($30.03M) | - | ($21.65M) | ($20.06M) | ($15.75M) | - | ($39.09M) | ($12.80M) | ($12.97M) | - |
| EPS - Basic | ($0.29) | - | ($0.24) | ($0.23) | ($0.18) | - | ($0.64) | ($0.24) | ($0.26) | - |
| EPS - Diluted | ($0.29) | - | ($0.24) | ($0.23) | ($0.18) | - | ($0.64) | ($0.24) | ($0.26) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73.59M | $124.25M | $49.97M | $53.37M | $71.00M | $91.42M | $75.80M | $47.75M | $43.98M | $56.98M |
| Accounts Receivable | $13.02M | $16.20M | $14.38M | $9.95M | $10.97M | $8.14M | $13.47M | $12.92M | $11.35M | $17.73M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $12.68M | $12.99M | $11.15M | $9.93M | $7.91M | $6.40M | $12.45M | $9.94M | $9.18M | $14.92M |
| Current Assets | $258.20M | $267.95M | $174.40M | $193.34M | $206.42M | $203.01M | $170.28M | $113.10M | $120.44M | $146.74M |
| Total Assets | $325.39M | $334.16M | $242.84M | $258.68M | $273.31M | $270.27M | $239.89M | $185.50M | $195.28M | $225.10M |
| Current Liabilities | $39.05M | $39.63M | $36.16M | $31.72M | $29.89M | $31.13M | $36.41M | $34.13M | $31.37M | $47.23M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $70.63M | $72.98M | $71.42M | $67.85M | $65.96M | $67.31M | $73.13M | $73.23M | $74.58M | $95.66M |
| Stockholders' Equity | $254.76M | $261.19M | $171.41M | $190.83M | $207.34M | $202.96M | $166.76M | $112.27M | $120.69M | $129.44M |
| Retained Earnings | ($661.29M) | ($631.26M) | ($607.45M) | ($585.80M) | ($565.74M) | ($549.99M) | ($533.57M) | ($494.48M) | ($481.67M) | ($468.71M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.48M) | - | - | - | ($17.96M) | - | - | - | ($20.41M) | - |
| Investing Cash Flow | ($46.01M) | - | - | - | ($22.54M) | - | - | - | $6.30M | - |
| Financing Cash Flow | $17.83M | - | - | - | $20.09M | - | - | - | $1.13M | - |
| CapEx | $3.19M | - | - | - | $2.51M | - | - | - | $104.0K | - |
| Free Cash Flow | ($25.67M) | - | - | - | ($20.47M) | - | - | - | ($20.52M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 1.8% | - | 13.2% | 27.6% | 35.0% | - | 34.0% | 35.6% | 28.1% | - |
| Operating margin | -207.9% | - | -160.7% | -126.7% | -85.9% | - | -55.9% | -74.8% | -96.7% | - |
| EBITDA margin | -192.5% | - | -141.7% | -112.2% | -73.3% | - | -45.1% | -62.4% | -82.2% | - |
| Net margin | -194.1% | - | -149.4% | -116.6% | -76.4% | - | -152.0% | -56.7% | -66.4% | - |
| Free cash flow margin | -165.9% | - | - | - | -99.4% | - | - | - | -105.1% | - |
| FCF / Net income | 0.85 | - | - | - | 1.30 | - | - | - | 1.58 | - |
| R&D / Revenue | 94.0% | - | 84.0% | 72.0% | 61.3% | - | 45.4% | 57.4% | 65.4% | - |
| SG&A / Revenue | 115.7% | - | 89.9% | 82.4% | 59.5% | - | 44.5% | 53.0% | 59.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.2% | - | -8.9% | -7.8% | -5.8% | - | -16.3% | -6.9% | -6.6% | - |
| Return on equity | -11.8% | - | -12.6% | -10.5% | -7.6% | - | -23.4% | -11.4% | -10.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.61 | 6.76 | 4.82 | 6.09 | 6.91 | 6.52 | 4.68 | 3.31 | 3.84 | 3.11 |
| Quick ratio | 6.61 | 6.76 | 4.82 | 6.09 | 6.91 | 6.52 | 4.68 | 3.31 | 3.84 | 3.11 |
| Cash ratio | 1.88 | 3.14 | 1.38 | 1.68 | 2.38 | 2.94 | 2.08 | 1.40 | 1.40 | 1.21 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -684.3x | - | -363.9x | -454.3x | -632.0x | - | -2054.6x | -1877.0x | -2097.8x | - |
| Equity multiplier | 1.28 | 1.28 | 1.42 | 1.36 | 1.32 | 1.33 | 1.44 | 1.65 | 1.62 | 1.74 |
| Liabilities / Assets | 0.22 | 0.22 | 0.29 | 0.26 | 0.24 | 0.25 | 0.30 | 0.39 | 0.38 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.06 | 0.07 | 0.08 | - | 0.11 | 0.12 | 0.10 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 307d | - | 362d | 211d | 194d | - | 191d | 209d | 212d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 305d | - | 323d | 291d | 216d | - | 268d | 249d | 239d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.6x | - | 3.4x | 3.0x | 1.5x | - | 2.0x | 0.5x | 0.6x | - |
| P / S | 42.9x | - | 39.9x | 33.8x | 14.9x | - | 12.8x | 2.7x | 3.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -24.9% | - | -43.6% | -23.8% | 5.5% | - | 40.9% | 35.2% | 3.5% | - |
| Revenue CAGR (3y) | -6.4% | - | -0.8% | -1.9% | 10.6% | - | 4.9% | 1.4% | -2.2% | - |
| Revenue CAGR (5y) | -5.8% | - | -6.1% | -2.5% | 1.5% | - | 17.1% | 20.7% | - | - |
| Gross profit growth (YoY) | -96.1% | - | -78.1% | -40.8% | 31.2% | - | 151.2% | 67.7% | 16.1% | - |
| Operating income growth (YoY) | -81.7% | - | -61.9% | -29.1% | 6.3% | - | 53.3% | 33.4% | 36.7% | - |
| Net income growth (YoY) | -90.7% | - | 44.6% | -56.7% | -21.5% | - | -34.3% | 46.6% | 54.8% | - |
| EPS growth (YoY) | -61.1% | - | 62.5% | 4.2% | 30.8% | - | -6.7% | 52.0% | 58.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -25.4% | - | - | - | 0.2% | - | - | - | -5.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 22.9% | 28.7% | 2.8% | 70.0% | 71.8% | 56.8% | 10.3% | -36.2% | -37.7% | -40.7% |
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Personalis against the 5 most active filers in the same SIC group.